Nathan Rice
Stock Analyst at Piper Sandler
(4.02)
# 592
Out of 4,711 analysts
50
Total ratings
56.25%
Success rate
11.78%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBIN Merchants Bancorp | Maintains: Overweight | $48 → $53 | $36.15 | +45.23% | 6 | Nov 26, 2024 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $37.90 | +24.01% | 3 | Nov 1, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $29.22 | +16.36% | 8 | Oct 29, 2024 | |
| BFC Bank First | Maintains: Neutral | $99 → $104 | $101.55 | +2.41% | 5 | Oct 17, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $44.36 | +66.82% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $106.01 | -20.76% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $211.06 | -6.66% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $11.63 | -22.61% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $412.26 | +5.52% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $276.92 | -15.86% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $59.58 | +39.31% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $17.66 | -15.06% | 1 | Dec 19, 2019 |
Merchants Bancorp
Nov 26, 2024
Maintains: Overweight
Price Target: $48 → $53
Current: $36.15
Upside: +45.23%
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $37.90
Upside: +24.01%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $29.22
Upside: +16.36%
Bank First
Oct 17, 2024
Maintains: Neutral
Price Target: $99 → $104
Current: $101.55
Upside: +2.41%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $44.36
Upside: +66.82%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $106.01
Upside: -20.76%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $211.06
Upside: -6.66%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $11.63
Upside: -22.61%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $412.26
Upside: +5.52%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $276.92
Upside: -15.86%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $59.58
Upside: +39.31%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $17.66
Upside: -15.06%